Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism; moderately severe/severe androgen dependent loss of scalp hair (moderately severe/severe androgenic alopecia); moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. apo-cyproterone acetate 50mg inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused by either increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if apo-cyproterone acetate 50mg is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation. men: reduction of drive in sexual deviations. apo-cyproterone acetate 50mg reduces the force of the sexual urge in men with sexual deviations. whilst under treatment the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a prerequisite for therapy is the desire by the patient for treatment. apo-cyproterone acetate 50mg should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social reorientation. inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - magnesium acetate,potassium acetate,sodium chloride - solution - 0.320,1.28,2.34 mg/ml,

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - magnesium acetate,potassium acetate,sodium chloride - solution - 0.32,1.28,2.34 mg/ml,

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - magnesium acetate,potassium acetate,sodium chloride - solution - 0.32,1.28,2.34 mg/ml,

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - magnesium acetate,potassium acetate,sodium chloride - solution - 0.32,1.28,2.34 mg/ml,

Europska Unija - engleski - EMA (European Medicines Agency)

gedeon richter plc. - ulipristal acetate - leiomyoma - sex hormones and modulators of the genital system, - ulipristal acetate is indicated for one treatment course of pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age who are not eligible for surgery.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

pharmaceutical associates, inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 40 mg in 1 ml - megestrol acetate oral suspension, usp is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). history of hypersensitivity to megestrol acetate or any component of the formulation. known or suspected pregnancy.

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - sodium chloride,sodium acetate,dextrose, calcium chloride,magnesium chloride,potassium chloride - solution - 214.77,166.72,77,9,5.34,5.22 g/l,

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - sodium chloride,sodium acetate,dextrose,potassium chloride, calcium chloride,magnesium chloride - solution - 199.22,174.34,17.325,6.78,6.43,5.34 g/l,